Company news
Dyne Therapeutics, Inc. news in 2022
Dyne Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
November 2, 2022
Dyne Therapeutics to Present at Investor Conferences in November
November 1, 2022
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
October 30, 2022
Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress
October 10, 2022
Dyne Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference
September 26, 2022
Dyne Therapeutics Highlights DM1 and DMD Clinical Programs During “Spotlight on the Clinic” Virtual Event
September 11, 2022
Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
September 5, 2022
Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
September 5, 2022
Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
September 5, 2022
Dyne Therapeutics Appoints Francesco Bibbiani, M.D., as Senior Vice President, Head of Development
August 28, 2022
Dyne Therapeutics Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research
August 9, 2022
Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
August 3, 2022
Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
July 11, 2022
Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
July 4, 2022
Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Leads to Robust DMPK RNA Knockdown
May 15, 2022
Dyne Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
May 1, 2022
Dyne Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
March 9, 2022
Dyne Therapeutics Appoints Carlo Incerti, M.D., to its Board of Directors
March 2, 2022
Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy
January 17, 2022
Dyne Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 4, 2022
Decks in 2022
- American Society of Gene & Cell Therapy 2022
Conference · 15 slides · May 16, 2022